Outlook Therapeutics, Inc. (OTLK) has secured $18.4 million in non-convertible note financing while amending its existing convertible note agreements, significantly enhancing its cash position as it prepares to commercialize its ophthalmic therapy, LYTENAVA. This financing is crucial for supporting European launches and regulatory activities in the U.S., marking a transition for Outlook from a clinical-stage biotech to a revenue-generating entity.
The company expects to net approximately $17 million from this financing, reducing its existing note obligations to about $10.8 million. The new note carries an interest rate tied to the Prime Rate, maturing in June 2027. Despite a recent drop in stock price to a 52-week low of $0.34, shares rebounded to $0.41 in overnight trading, reflecting market optimism surrounding the funding and Outlook’s future prospects.
This development underscores the importance of liquidity in biotech transitions. For a deeper dive into Outlook’s strategy and market implications, I recommend reading the full article.
Source: nasdaq.com